Pharmaceutical Business review

Evotec Acquires Majority Stake In Research Support International

Evotec has reported that the acquisition of the controlling majority stake of Research Support International (RSIPL) has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

The purchase price for the 70% controlling majority stake payable, before adjustments, to DIL is E2.8m in cash, a portion of which includes a potential earn-out. Evotec has a call option to purchase the remaining 30% from DIL in the future in the event of a change of control.

Reportedly, following the transaction, RSIPL will be integrated into the value chain of Evotec’s operations in Hamburg (Germany), Abingdon (UK) and Singapore.